PSILOCD

This single-blind study (n=20) investigates the enduring effects of psilocybin (10mg, 2x) on OCD symptoms, focusing on the activation of the 5-HT2A receptor and its impact on behavioural deficits associated with OCD.

The study, conducted at the CNWL-Imperial Psychopharmacology and Psychedelic Research (CIPPRes) Clinic at St. Charles Hospital, involves 20 patients with OCD (Y-BOCS score ≥ 16) receiving 2 doses of psilocybin (maximum 10mg) during three visits.

The primary outcomes, assessed at 1-week pre-psilocybin, 4 weeks after the first dose, and 4 weeks after the second, include changes in the ID-ED set-shifting task, Y-BOCS scores, and the visual long-term potentiation (LTP) EEG task.

Recruitment started on 07 Sep 2022 and will end on 01 May 2024. This interventional trial is sponsored by the Imperial College of Science, Technology and Medicine and funded by ORCHARD. Participants, aged 20 to 65, of any gender, with a primary diagnosis of OCD (DSM-IV or ICD-10), a Y-BOCS score ≥ 16, and a history of OCD for at least 12 months, are eligible. The study excludes individuals with specific medical conditions, substance use history, psychosis, mania, severe adverse effects after psychedelic use, and other criteria mentioned. The trial involves 12 remote calls and visits, combining preparation, psychological debriefing, and data collection through psychiatric interviews, questionnaires, and cognitive tasks.

Topic Obsessive-Compulsive Disorder
Compound Psilocybin
Visit trial
Status Recruiting
Results Published No
Start date 07 September 2022
End date 01 May 2024
Design Blinded
Type Interventional
Generation First
Participants 20
Sex All
Age 20- 65
Therapy No

Trial Details

This study, sponsored by Imperial College and funded by ORCHARD, investigates the lasting effects of psilocybin on OCD symptoms in 20 patients at CNWL-Imperial CIPPRes Clinic. Recruitment began on 07 Sep 2022, ends on 01 May 2024. Participants aged 20-65 with OCD undergo remote calls and visits. Exclusions apply based on medical and psychiatric history.

NCT Number CPMS 50985

Sponsors & Collaborators

Imperial College London
The Centre for Psychedelic Research studies the action (in the brain) and clinical use of psychedelics, with a focus on depression.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.